Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats

Hypertension

Volumn 53, Issue 5, 2009, Pages 775-781

  Mukaddam Daher, Suhayla ^a   Menaouar, Ahmed ^a   Paquette, Pierre Alexandre ^a   Jankowski, Marek ^a   Gutkowska, Jolanta ^a   Gillis, Marc Antoine ^b   Shi, Yan Fen ^b   Calderone, Angelo ^b   Tardif, Jean Claude ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Eprosartan; Hemodynamics; Hypertension; Hypertrophy; Moxonidine; Natriuretic peptides

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPROSARTAN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MOXONIDINE; NATRIURETIC FACTOR; PROTEIN BAX; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR EFFECT; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART RATE; HEMODYNAMICS; HYPERTENSION; LONG TERM CARE; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; TELEMETRY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

ACRYLATES; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; HEART RATE; HYPERTENSION; IMIDAZOLES; MALE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; RATS; RATS, INBRED SHR; STROKE; THIOPHENES; VENTRICULAR FUNCTION, LEFT;

EID: 73549088317     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.126524     Document Type: Article

References (36)

1. Esler M. Sympathetic nervous system: contribution to human hypertension and related cardiovascular diseases. J Cardiovasc Pharmacol. 1995; 26:S24-S28. (Pubitemid 26073319)
2. Morgan T. Renin, angiotensin, sodium and organ damage. Hypertens Res. 2003; 26:349-354. (Pubitemid 36701675)
3. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol. 2007; 292:C82-C97.
4. Agabiti-Rosei E, Muiesan ML, Salvetti M. Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy. J Am Soc Nephrol. 2006; 17: S104-S108.
5. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B, for the LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events: the LIFE Study. JAMA. 2004; 292:2343-2349.
6. Signolet IL, Bousquet PP, Monassier LJ. Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in onekidney, one-clip hypertensive rabbits. Am J Hypertens. 2008; 21:54-60.
7. Perlini S, Ferrero I, Palladini G, Tozzi R, Gatti C, Vezzoli M, Cesana F, Janetti MB, Clari F, Busca G, Mancia G, Ferrari AU. Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure. Hypertension. 2006; 48:93-97. (Pubitemid 44297529)
8. Cohn JN. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Adv Ther. 2007; 24:1290-1304. (Pubitemid 351618138)
9. Paquette P-A, Duguay D, El-Ayoubi R, Menaouar A, Danalache B, Gutkowska J, DeBlois D, Mukaddam-Daher S. Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation. Br J Pharmacol. 2008; 153:459-467. (Pubitemid 351199016)
10. Farsang C, Lengyel M, Borbás S, Zorándi A, Dienes BS, for the VERITAS Investigators. Value of rilmenidine therapy and its combination with Perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS). Curr Med Res Opin. 2003; 19:205-217. (Pubitemid 36613004)
11. Okamoto K, Yamori Y, Nagaoka A. Establishment of the strokeprone spontaneously hypertensive rat (SHR). Circ Res. 1974; 34/35:143-153.
12. Behr TM, Willette RN, Coatney RW, TBerova M, Angermann CE, Anderson K, Sackner-Bernstein JD, Barone FC. Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease. J Hypertens. 2004; 22:583-592. (Pubitemid 38368493)
13. Menaouar A, El-Ayoubi R, Jankowski M, Gutkowska J, Mukaddam-Daher S. Chronic imidazoline receptor activation in spontaneously hypertensive rats. Am J Hypertens. 2002; 15:803-808. (Pubitemid 34970110)
14. Gutkowska J. Radioimmunoassay for atrial natriuretic factor. Nucl Med Biol. 1987; 14:323-331.
15. Reffelmann T, Kloner RA. Trans-thoracic echocardiography in rats. Evaluation of commonly used indices of left ventricular dimensions, con tractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc-facp-Rats) in comparison with Wistar rats during aging. Basic Res Cardiol. 2003; 98:275-284. (Pubitemid 37107654)
16. Nguyen QT, Colombo F, Clement R, Rouleau JL, Calderone A. ATI receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodeling post-MI. Br J Pharmacol. 2003; 138:1485-1494. (Pubitemid 36609644)
17. Jankowski M, Wang D, Mukaddam-Daher S, Gutkowska J. Pregnancy alters nitric oxide synthase and natriuretic peptide systems in the rat left ventricle. J Endocrinol. 2005; 184:209-217. (Pubitemid 40207575)
18. Rigsby CS, Burch AE, Ogbi S, Pollock DM, Dorrance AM. Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. Am J Physiol. 2007; 293:R1754-R1763. (Pubitemid 47535795)
19. Aitman TJ, Gotoda T, Evans AL, Imrie H, Heath KE, Trembling PM, Truman H, Wallace CA, Rahman A, Dore C, Flint J, Kren V, Zidek V, Kurtz TW, Pravenec M, Scott J. Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats. Nat Genet. 1997; 16:197-201. (Pubitemid 27240622)
20. Amann K, Greber D, Gharehbaghi H, Wiest G, Lange B, Ganten U, Mattfeldt T, Mall G. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Am J Hypertens. 1992; 5:76-83.
21. Friddle CJ, Koga T, Rubin EM, Bristow J. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci U S A. 2000; 97:6745-6750. (Pubitemid 30412785)
22. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Inhibition of facilitation of sympathetic neurotransmission and angiotensin Il-induced pressor effects in the pithed rat: comparison between valsaran, candesartan, eprosartan and embusartan. J Hypertens. 2001; 19:2241-2250. (Pubitemid 33135247)
23. Heusser K, Vitkovsky J, Raasch W, Schmieder RE, Schobel HP. Elevation of sympathetic activity by eprosartan in young male subjects. Am J Hypertens. 2003; 16:658-664. (Pubitemid 36900589)
24. Gao L, Wang W, Wang W, Li H, Sumners C, Zucker IH. Effects of angiotensin type 2 receptor overexpression in the rostral ventrolateral medulla on blood pressure and urine excretion in normal rats. Hypertension. 2008; 51:521-527. (Pubitemid 351156442)
25. Min LJ, Mogi M, Iwanami J, Li JM, Sakata A, Fujita T, Tsukuda K, Iwai M, Horiuchi M. Angiotensin II type 2 receptor deletion enhances vascular senescence by methyl methanesulfonate sensitive 2 inhibition. Hypertension. 2008; 51:1339-1344. (Pubitemid 351555947)
26. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartantreated chronic renal failure. J Am Soc Nephrol. 2004; 15:2902-2907. (Pubitemid 41103399)
27. Diaz A, Bourassa MG, Guertin M-C, Tardif J-C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005; 26:967-974. (Pubitemid 40695027)
28. Fox K, Borer JS, Camm AJ, DanchinN, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M, for the Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007; 50: 823-830.
29. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008; 101:865-869.
30. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, Mancia G. Heart rate as a marker of sympathetic overactivity. J Hypertens. 1998; 16:635-1639.
31. Huang MH, Friend DS, Sunday ME, Singh K, Haley K, Austen KF, Kelly RA, Smith TW. An intrinsic adrenergic system in mammalian heart. J Clin Invest. 1996; 98:1298-1303. (Pubitemid 26322054)
32. Armour JA. Potential clinical relevance of the 'little brain' on the mammalian heart. Exp Physiol. 2008; 93:165-176.
33. El-Ayoubi R, Gutkowska J, Regunathan S, Mukaddam-Daher S. Imidazoline receptors in the heart: characterization, distribution, and regulation. J Cadiovasc Pharmacol. 2002; 39:875-883. (Pubitemid 34538818)
34. El-Ayoubi R, Menaouar A, Gutkowska J, Mukaddam-Daher S. Imidazoline receptors but not alpha2 adrenoceptors are regulated in SHR heart by chronic moxonidine treatment. J Pharmacol Exper Therap. 2004; 310:446-451.
35. Mukaddam-Daher S, Menaouar A, Gutkowska J. Receptors involved in moxonidine-stimulated ANP release from isolated hearts of normotensive rats. Eur J Pharmacol. 2006; 541:73-79. (Pubitemid 43903474)
36. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J MoI Cell Cardiol. 2007; 42:271-279. (Pubitemid 46135596)